Anthracyclines Induce DNA Damage Response-Mediated Protection against Severe Sepsis by Figueiredo, Nuno et al.
 1 
 
Immunity, Volume 39 
Supplemental Information 
Anthracyclines Induce DNA Damage  
Response-Mediated Protection against Severe Sepsis 
 
Nuno Figueiredo, Angelo Chora, Helena Raquel, Nadja Pejanovic, Pedro Pereira, 
Björn Hartleben, Ana Neves-Costa, Catarina Moita, Dora Pedroso, Andreia Pinto, 
Sofia Marques, Hafeez Faridi,  Paulo Costa, Raffaella Gozzelino, Jimmy L. Zhao, 
Miguel P. Soares,  Margarida Gama-Carvalho, Jennifer Martinez, Qingshuo Zhang, 
Gerd Döring, Markus Grompe, J. Pedro Simas, Tobias B. Huber, David Baltimore, 
Vineet Gupta, Douglas R. Green, João A. Ferreira
 
and Luis F. Moita 
 
Supplemental Inventory 
1. Supplemental Figures and Tables 
 Figure S1, Related to Figure 1 
 Figure S2, Related to Figure 2 
 Figure S3, Related to Figure 3 
 Figure S4, Related to Figure 4 
 Figure S5, Related to Figure 5 
 Table S1, Related to Figure 1 
 Table S2, Related to Figure 3 
2. Supplemental Experimental Procedures 
3. Supplemental References 
 
 
 
 
 
 
 
 
 2 
Supplemental Figures 
 
 
 3 
 
 
Figure S1 – Anthracyclines inhibit the secretion of TNF and IL-1β.  
(a) Two-dimension plot of TNF and IL-1β production Z scores. The grey square defines 
the area in which compounds are considered primary hits, i.e., inhibiting both TNF and 
IL-1β. Black dots identify epirubicin (1), daunorubicin (2) and doxorubicin (3). 
(b) THP-1 cell viability upon E. coli challenge (4 hours) after a pre-incubation (1 hour) 
with increasing concentrations of epirubicin (left panel), daunorubicin (middle panel) and 
doxorubicin (right panel).  
(c) IL-1β and TNF production by E. coli challenged THP-1 cells (4 hours) after a pre-
incubation (1 hour) with increasing concentrations of epirubicin (left panel), 
daunorubicin (middle panel) and doxorubicin (right panel).  
(d) Survival of C57BL/6 wild-type animals subjected to CLP treated with carrier (PBS) 
or epirubicin (0.6µg/g body weight) intraperitoneally (Epi IP) or intraveneouslly (Epi IV) 
at the time of procedure and 24 hours later. Results shown represent arithmetic means ± 
SD from duplicate samples in one of 3 independent assays. ns, not significant; *P<0.05; 
**P<0.01 ***P<0.001 (Mann-Whitney test for (c); log-rank (Mantel-Cox) for (d)). 
Related to Figure 1. 
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Figure S2 - Hematoxylin and eosin representative sections of lung, liver, kidney, 
heart and intestine of mice subjected to mock CLP (S) or CLP followed by treatment 
with PBS (C+P) or epirubicin (C+E) as in (a) and isolated 24 hours after the procedure. 
Original magnification 20X. Related to Figure 2. 
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Figure S3 – The anti-inflammatory effects of epirubicin are mediated by ATM.  
(a) Two-dimension Z score plot of TNF and IL-1β production by THP-1 cells upon target 
gene knockdown using a selected group of constructs of the TRC shRNA lentiviral vector 
library followed by PFA-fixed E. coli stimulation for 24 hours. Each dot represents an 
individual construct. Dotted horizontal and vertical lines define the area in which genes 
are considered primary hits. Black dots identify ATM (1), ATR (2) and CHECK1 (3).  
(b) Epirubicin activates ATM as shown by Flow cytometry analysis of the activated 
form of ATM, phosphorilated at serine 1981, in THP-1 cells left untreated (C) or treated 
with epirubicin alone (1µM) (5 hours) (Epi), challenged with PFA-fixed E. coli (4 hours) 
(E. coli) or E. coli (4 hours) plus epirubicin pre-treatment (1 hour) (E. coli + Epi), and  
(c) Immunoblotting of total protein extracts of THP-1 cells untreated or pre-treated with 
epirubicin (1mM) and challenged with PFA-fixed E. coli at indicated timepoints probed 
for the total and phosphorylated (serine 1981) forms of ATM.  
(d) and (e) IL-1β and TNF production by (d) THP-1 cells and (e) BMDM following E. 
coli challenge (4 hours) after a pre-incubation (1 hour) with carrier, epirubicin or KU-
55933 as indicated. Results shown represent arithmetic means ± SD from triplicate 
samples for one of at least 3 independent assays.  
(f) IL-1β and TNF production by Atm+/+ and Atm-/- BMDM following E. coli challenge 
and pre-incubation with carrier or epirubicin as in (e). ns, not significant; *P<0.05; 
**P<0.01 ***P<0.001 (Unpaired t test for (d) to (f)). Related to Figure 3. 
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Figure S4 – In vivo protective effect of epirubicin is not due to either ROS 
scavenging, decreased neutrophils or induced miR-146a biogenesis.  
(a) ROS content in THP-1 cells as assessed by the pan ROS probe CM-H2DCFDA 
following E. coli challenge (4 hours) after a pre-incubation (1 hour) with carrier, 
epirubicin or KU-55933 as indicated. Results shown represent arithmetic means ± SEM 
from 3 independent assays.  
(b) Survival of Nrf2
+/+
 and Nrf2
-/- 
animals subjected to CLP and treated with PBS or 
epirubicin (0.6µg/g body weight) (Epi) at the time of procedure and 24 hours later.  
(c) Evaluation of apoptosis (AnnexinV
+
 cells) in total splenocytes of C57BL/6 wild-type 
animals subjected to CLP and treated with PBS or epirubicin as in (b) at the indicated 
times. Each circle represents individual animals and horizontal lines indicate arithmetic 
means ± SEM from two independent assays.  
(d) Quantification of total cells, neutrophils, B cells, CD4 T and CD8 T lymphocytes in 
the peritoneal cavity 18 hours post CLP of C57BL/6 wildtype animals treated with PBS 
or epirubicin (0.6 g/g body weight) at the time of procedure.  
(e) Survival of miR 146a
+/+
 and miR146a
-/- 
animals subjected to CLP and treated with 
PBS or epirubicin as in (b).  
(f) miR-146a expression, as assessed by qRT-PCR, in THP-1 cells left untreated or pre-
treated with epirubicin and challenged with PFA-fixed E. coli for the indicated times. ns, 
not significant; *P<0.05; **P<0.01; ***P<0.001 (unpaired t test for (a), (c) and (d); log-
rank (Mantel-Cox) test for (b) and (e)). Related to Figure 4. 
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Figure S5 – Decreased expression of Atg7 in the lung of Atg7loxP/loxP AdCre animals. 
(a) ATG7 protein levels by immunoblotting in lung of 3 wild-type (B6) and 3 Atg7
loxP/loxP
 
animals 5 days after inhalation of adenoviral vector encoding Cre (Ad
Cre
). Related to 
Figure 5. 
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Supplemental Tables 
 
ID MOLECULE NAME Z score TNFa Z score IL1b 
1505708 EPIRUBICIN HYDROCHLORIDE -4.474857631 -1.212875226 
300037 CRASSIN ACETATE -4.448741528 -2.126298968 
1501193 ERYSOLIN -4.442389411 -1.162701697 
1504079 TOMATINE -4.440219344 -2.626087857 
330001 DACTINOMYCIN -4.13760156 -1.187827575 
1505483 DOXORUBICIN -4.071115136 -2.412138965 
200007 GAMBOGIC ACID -3.862359373 -1.529656531 
200090 OBTUSAQUINONE -3.829374842 -1.532189516 
200022 AKLAVINE HYDROCHLORIDE -3.511681732 -1.408917561 
1504181 PRISTIMERIN -3.474946679 -0.952562058 
1505955 COLISTIN SULFATE -3.457325884 -0.918619053 
1504082 DIHYDROCELASTROL -3.387513735 -1.102010407 
1505908 MANGOSTIN TRIMETHYL ETHER -3.162805301 -1.634164354 
1504218 ACRISORCIN -3.10607388 -0.959612692 
300549 ACETYL ISOGAMBOGIC ACID -3.056795183 -1.48116787 
201522 GAMBOGIC ACID AMIDE -3.013926221 -1.517154207 
1500223 DAUNORUBICIN -3.007093086 -0.995459172 
201604 PYRROMYCIN -2.980583694 -1.456377283 
1500260 PYRITHIONE ZINC -2.951809549 -1.872292546 
201664 CELASTROL -2.941287145 -1.499560887 
1500319 GRAMICIDIN -2.91855912 -1.84556962 
1503006 BENZYL ISOTHIOCYANATE -2.908582737 -1.034306584 
1503904 PATULIN -2.874616362 -0.902703858 
1503640 PARTHENOLIDE -2.842267433 -0.921962794 
100005 ANTHOTHECOL -2.834385142 -1.868706598 
100009 CEDRELONE -2.817231786 -1.852572153 
1504098 PHENOTHRIN -2.810792588 -0.982918754 
1505438 HYDROCORTISONE VALERATE -2.794271243 -2.722889618 
1504240 1,4-NAPHTHOQUINONE -2.77797604 -1.349015947 
1505450 PREDNISOLONE HEMISUCCINATE -2.72427413 -2.095888301 
1500315 GENTIAN VIOLET -2.696385799 -1.835724332 
310010 HELENINE -2.683894042 -0.943744357 
310035 SANGUINARINE SULFATE -2.651620816 -1.160017114 
1503074 ALEXIDINE HYDROCHLORIDE -2.648173863 -0.941221729 
1503278 MITOXANTHRONE HYDROCHLORIDE -2.562729474 -1.158920135 
1505723 BETAMETHASONE ACETATE -2.560814606 -0.950513609 
100146 7-DESACETOXY-6,7-DEHYDROGEDUNIN -2.517707805 -1.789647817 
1503432 MEPARTRICIN -2.504992413 -1.081865327 
201524 DIHYDROGAMBOGIC ACID -2.488781431 -1.48996453 
1505722 DESOXYMETASONE -2.417754689 -0.995122645 
1505726 DESONIDE -2.297715909 -0.945977097 
1500521 PYRVINIUM PAMOATE -2.268148981 -1.683811286 
1505168 ETHACRIDINE LACTATE -2.218841761 -1.389229184 
1501149 RITODRINE HYDROCHLORIDE -2.149761571 -1.268303571 
1505125 ALCLOMETAZONE DIPROPIONATE -1.999200408 -0.922964076 
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Supplemental Table S1 – List of drug candidates with a simultaneous effect on TNF and 
IL-1  secretion sorted according to the TNF score. Related to Figure 1. 
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GENE SYMBOL Z score IL1b 
RXRG 13.98549908 
CERK 13.39528156 
CDC2L2 12.99841134 
CIB3 12.75588891 
PINK1 10.89465184 
MAP2K1IP1 10.14345798 
SSH2 8.026894031 
PANK4 7.718714959 
EP300 7.623445834 
AK7 7.394176161 
NEK8 6.751890843 
OBSCN 6.321377789 
PKMYT1 6.226621005 
HRAS 6.149535407 
TRAF3IP3 6.002379966 
NR1I3 5.95185992 
MKNK1 5.779260808 
LRRK1 5.719405322 
RIPK2 5.660988701 
GMIP 5.47911595 
EGFR 5.412317129 
GABRA3 5.359381956 
TAF1 5.010952334 
PGK2 4.917770486 
PPP2R5A 4.857120549 
UNK 4.771385393 
GKAP1 4.683529402 
TPD52L3 4.673580927 
CNKSR3 4.618895483 
INPP5D 4.438107961 
ANP32A 4.395832296 
ATPBD3 4.382323214 
OTOF 4.208122584 
ATR 4.112577436 
CMPK 3.993795701 
GABRA5 3.874921808 
NR1H4 3.823781917 
FASTK 3.778931417 
UNK 3.732009689 
ACVR1B 3.594003404 
PFKP 3.491304822 
NEK1 3.447427342 
MYB 3.405296434 
GLI2 3.384979498 
LOC392265 3.321683768 
PHKG2 3.302428028 
CSNK1E 3.245684303 
MGC16169 3.228807399 
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NRGN 3.095045302 
PPP4R2 3.087946219 
CHEK1 2.948032051 
IKBKE 2.922117318 
NRK 2.802732447 
RET 2.790558375 
NR1I2 2.789827176 
PCK2 2.725958526 
PIK3AP1 2.669418039 
NF1 2.639991401 
NME2 2.556120026 
MAP3K11 2.534703827 
RIMS4 2.5316375 
UNK 2.478795985 
KHK 2.438721798 
ATM 2.416357404 
IHPK3 2.415439713 
RBL1 2.315787477 
PRKCDBP 2.313302238 
UNK 2.301598358 
KRAS 2.272676173 
PIK3CD 2.235319365 
IGF1R 2.201867854 
LOC442558 2.195176609 
CDK5R1 2.105595811 
MEN1 2.047194355 
 
Supplemental Table S2 -  shRNA-based identification of negative regulators of IL-1β 
secretion in response to E. coli, in THP-1 cells. Related to Figure 3. 
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Supplemental Experimental Procedures 
 
Figure S1 
Chemical Screen 
THP-1 human monocytes were plated in 96-well plates at 10
6 cell/ml and incubated with 
each of the ~2320 compounds included in the Spectrum collection (Microsource 
Discovery Systems, Gaylordsville, CT) at 10 M for 1 hour. Cells were challenged with 
4% PFA-fixed DH5a E.coli at a Multiplicity of Infection (MOI) of 20 bacterial cells per 
THP-1 cell for an additional 24 hours. The cell supernatants were collected and IL-1β and 
TNF cytokines quantified by DAS-ELISA, using Human IL-1β /IL-1F2 DuoSet® and 
Human TNF DuoSet® (R&D Systems®), respectively. 
 
Figure S3 
While epirubicin decreased both IL-1β and TNF secretion in THP-1 cells, only IL-1β, but 
not TNF, was up-regulated after ATM or ATR silencing (Supplemental Table S2 and 
S3). Similar results were obtained in THP-1 cells using the ATM specific pharmacologic 
inhibitor KU-55933 (Figure S3d). Similarly, treatment of bone marrow-derived 
macrophages with epirubicin inhibited IL-1β and TNF secretion (Figure S3e). However, 
this inhibition was also observed in ATM-deficient bone marrow derived macrophages, 
suggesting that epirubicin can inhibit IL-1β secretion via a mechanism that is not strictly 
ATM dependent (Figure S3f). 
 
The RNAi Consortium Library 
Detailed description of the RNAi Consortium (TRC) lentiviral RNAi library used in this 
study was originally described in (Moffat et al., 2006). More details can be found at  
www.broad.mit.edu/rnai/trc/lib. 
 
shRNA-based Screen 
We generated a working subset of The RNAi Consortium (TRC) shRNA lentiviral vector 
library (Moffat et al., 2006) that allows for the silencing of most of the genes that are 
either human kinases or phosphatases. This subset was composed of 1440 individually 
arrayed lentiviral shRNA vectors targeting ~700 genes, after selecting the most efficient 
shRNAs (two on average) based on available silencing efficiency data from the Broad 
Institute of MIT and Harvard. THP-1 cells were plated in 96-well plates at 10
6
 cell/ml and 
infected with shRNA-expressing lentivirus. 48 hrs later infected cells were selected with 
puromycin. After the 3 days of selection, plates were duplicated. One of the plates was 
used to measure the cell number using Alamar Blue® cell viability assay (Invitrogen®). In 
the other plate, cells were stimulated with 4% PFA-fixed DH5a E.coli at a Multiplicity of 
Infection (MOI) of 20 bacterial cells per THP-1 cell. Twenty-four hours after stimulation, 
cell supernatants were collected and IL-1β and TNF cytokines quantified by DAS-
ELISA. All data values from IL-1β and TNF secretion assays were normalized by 
dividing the amount of IL-1β and TNF in the conditioned media 24, 12, 8, 6, 4 or 2 hrs 
after E. coli stimulation by the number of cells in each well and then by the average 
concentration per cell of the plate. Results were logarithmic natural transformed. Scores 
were sorted in ascending order and graphed. We calculated 1.5 SDEVs above and below 
the mean to identify the genes that changed IL-1β and TNF secretion when silenced. The 
 16 
same approach was used to identify the compounds that changed IL-1β and TNF 
secretion. The selected genes were submitted to two or more rounds of phenotypic 
validation. 
 
Figure S4 
We explored several additional possible ATM-dependent mechanisms to explain the 
protective role of epirubicin in sepsis. We found that, in vitro, epirubicin is able to 
counteract the increase in ROS generated by E. coli challenge of THP-1 cells in an ATM 
dependent manner (Figure S4a). However, mice that are deficient for the nuclear factor 
(erythroid-derived 2)-like 2 (NRF2), a master regulator of ROS scavenging (Lee et al., 
2005), are still protected by epirubicin against mortality due to CLP (Figure S4b). 
Therefore, epirubicin induces an ATM-dependent ROS scavenging response that is 
largely dispensable for its protective effect in sepsis. Increased apoptosis of neutrophils 
can attenuate sepsis pathogenesis (Garrison et al., 2011). This would be a simple and 
attractive hypothesis considering that anthracyclines initiate a DDR leading to increased 
apoptosis if the DNA lesion is too severe for repair (Garrison et al., 2011). However, our 
data shows that epirubicin treated mice have higher, not lower, numbers of viable 
neutrophils in the abdomen, excluding an important role for this mechanism (Figure S4c). 
 
The biogenesis of some miRNAs, including miR-146a (a negative regulator of 
inflammation (Taganov et al., 2007) and a proposed biomarker in sepsis (Wang et al., 
2010)), is ATM-dependent (Zhang et al., 2011). We compared the survival of wild-type 
mice with that of miR-146a –deficient mice in the presence or absence of epirubicin. We 
conclude that the protection given by this drug is dependent on the presence of miR-146a 
(Figure S4e). However, our RT-qPCR analysis of miR-146a expression in either RAW 
cells or THP-1 cells (Figure S4f) does not support a role for epirubicin in the induction of 
this microRNA. Therefore, direct induction of miR- 146a is not the mechanism by which 
epirubicin protects against the LPS model of septic shock or CLP. 
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